Remdesivir in COVID-19- new Cure or Illusion

Jose Chacko May 9, 2020 416

share close
Remdesivir in COVID-19

Remdesivir (also GS-5734) is a monophosphoramidate prodrug of an adenosine analogue that has a broad antiviral spectrum including filoviruses, paramyxoviruses, pneumoviruses, and coronaviruses. In vitro, remdesivir inhibits all human and animal coronaviruses tested to date, including SARS-CoV-2.

 Intravenous remdesivir was studied for treatment of Ebola virus disease, in which it was adequately tolerated but less effective than several monoclonal antibody therapeutics,and has been used on the basis of individual compassionate use over the past several months in patients with COVID-19 in some countries.

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Copyright- Dr Jose Chacko
Copyright- Dr Jose Chacko
Copyright- Dr Jose Chacko
Copyright- Dr Jose Chacko
Copyright- Dr Jose Chacko
Copyright- Dr Jose Chacko

Strengths –

Only RCT on this topic


•6 days difference; assuming 21 days with placebo. HR( expected- 1.43); HR (observed) – 1.23

•453 patients: 302: 151 ( randomisation 2:1 ) ???

•Terminated on March 12 with 237 patients due to effective lockdown measures; power was 58%

•Late treatment initiation

•Combination with other drugs, including steroids

•Dose, duration of treatment- uncertain

Copyright – Dr Jose Chacko

Conclusion –

Inconclusive evidence in support of Remdesivir.

Can be used in research context but its too early to call it as a CURE for COVID-19.

Rate it
Previous episode
Connecting Dots in COVID-19
eCritCare Podcast
share playlist_add
  • 621


Connecting Dots in COVID-19

Dr Swapnil Pawar April 27, 2020

The literature published from various countries has helped us to understand the disease pattern in COVID-19 pandemic. The New York experience Richardson et al. evaluated a large case series of […]

Read more trending_flat

Similar posts